MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics
Authors' conclusion
The 15 markers we identified can be employed to improve the diagnostic of cytologically indeterminate thyroid nodules.
Study context
- Population
- Thyroid nodules (PTC vs BTN); public reduced representative bisulfite sequencing dataset; Z.S.'s retrospective cohort (50 PTC and 18 BTN surgery-leftover samples) and preoperative cohort (31 PTC and 30 BTN fine-needle aspiration samples)
- Comparison
- MeIS for distinguishing papillary thyroid cancers (PTCs) from benign thyroid nodules (BTNs)
- Outcome
- AUC for distinguishing PTCs from BTNs
Methodological detailsclassifier development and validation, 2 independent validation cohorts
- Classifier development and validation
- 2 independent validation cohorts
Performance
As reported in the abstract
| Test or model | AUC, training set | AUC, validation set | AUC, Z.S.'s retrospective cohort | AUC, Z.S.'s preoperative cohort |
|---|---|---|---|---|
| MeIS | 0.96 | 0.98 | 0.89 | 0.90 |
MeIS
AUC, training set0.96
AUC, validation set0.98
AUC, Z.S.'s retrospective cohort0.89
AUC, Z.S.'s preoperative cohort0.90
Further findings
Cytologically indeterminate thyroid nodules, Z.S.'s retrospective cohort
Sensitivity
Specificity
Cytologically indeterminate thyroid nodules, Z.S.'s preoperative cohort
Sensitivity
Specificity
Original publication
MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics. J Clin Endocrinol Metab. Published 7 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →